Pilot study of antibodies against varicella zoster virus and human immunodeficiency virus in relation to the risk of developing stroke, nested within a rural cohort in Uganda

<p style="text-align:justify;"> Objective: The risk of stroke rises after episodes of herpes zoster and chickenpox, which are caused by varicella zoster virus (VZV). We conducted a pilot case–control study of stroke, nested within a long‐standing cohort in Uganda (the General Popula...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Asiki, G, Stockdale, L, Kasamba, I, Vudriko, T, Tumwekwase, G, Johnston, T, Kaleebu, P, Kamali, A, Seeley, J, Newton, R
Materialtyp: Journal article
Språk:English
Publicerad: Wiley 2015
_version_ 1826267410781437952
author Asiki, G
Stockdale, L
Kasamba, I
Vudriko, T
Tumwekwase, G
Johnston, T
Kaleebu, P
Kamali, A
Seeley, J
Newton, R
author_facet Asiki, G
Stockdale, L
Kasamba, I
Vudriko, T
Tumwekwase, G
Johnston, T
Kaleebu, P
Kamali, A
Seeley, J
Newton, R
author_sort Asiki, G
collection OXFORD
description <p style="text-align:justify;"> Objective: The risk of stroke rises after episodes of herpes zoster and chickenpox, which are caused by varicella zoster virus (VZV). We conducted a pilot case–control study of stroke, nested within a long‐standing cohort in Uganda (the General Population Cohort), to examine antibodies against VZV prior to diagnosis. Methods: We used stored sera to examine the evolution of IgG and IgM antibodies against VZV among 31 clinically confirmed cases of stroke and 132 matched controls. For each participant, three samples of sera were identified: one each, taken at or near the time of (pseudo)diagnosis, between 5 and 10 years prior to diagnosis and at 15 years prior to diagnosis. Results: All participants had detectable antibodies against VZV, but there were no significant differences between cases and controls in the 15 years prior to diagnosis. As a secondary finding, 16% (5/31) of cases and 6% (8/132) of controls had HIV (OR 3.0; 95% CI 0.8–10.1; P = 0.06). Conclusions: This is the first prospective study to examine a biological measure of exposure to VZV prior to diagnosis of stroke and although we identified no significant association, in this small pilot, with limited characterisation of cases, we cannot exclude the possibility that the virus is causal for a subset. The impact of HIV on risk of stroke has not been well characterised and warrants further study. </p>
first_indexed 2024-03-06T20:53:47Z
format Journal article
id oxford-uuid:387e70e8-9a4e-471c-823c-7fea64ba282c
institution University of Oxford
language English
last_indexed 2024-03-06T20:53:47Z
publishDate 2015
publisher Wiley
record_format dspace
spelling oxford-uuid:387e70e8-9a4e-471c-823c-7fea64ba282c2022-03-26T13:50:23ZPilot study of antibodies against varicella zoster virus and human immunodeficiency virus in relation to the risk of developing stroke, nested within a rural cohort in UgandaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:387e70e8-9a4e-471c-823c-7fea64ba282cEnglishSymplectic Elements at OxfordWiley2015Asiki, GStockdale, LKasamba, IVudriko, TTumwekwase, GJohnston, TKaleebu, PKamali, ASeeley, JNewton, R <p style="text-align:justify;"> Objective: The risk of stroke rises after episodes of herpes zoster and chickenpox, which are caused by varicella zoster virus (VZV). We conducted a pilot case–control study of stroke, nested within a long‐standing cohort in Uganda (the General Population Cohort), to examine antibodies against VZV prior to diagnosis. Methods: We used stored sera to examine the evolution of IgG and IgM antibodies against VZV among 31 clinically confirmed cases of stroke and 132 matched controls. For each participant, three samples of sera were identified: one each, taken at or near the time of (pseudo)diagnosis, between 5 and 10 years prior to diagnosis and at 15 years prior to diagnosis. Results: All participants had detectable antibodies against VZV, but there were no significant differences between cases and controls in the 15 years prior to diagnosis. As a secondary finding, 16% (5/31) of cases and 6% (8/132) of controls had HIV (OR 3.0; 95% CI 0.8–10.1; P = 0.06). Conclusions: This is the first prospective study to examine a biological measure of exposure to VZV prior to diagnosis of stroke and although we identified no significant association, in this small pilot, with limited characterisation of cases, we cannot exclude the possibility that the virus is causal for a subset. The impact of HIV on risk of stroke has not been well characterised and warrants further study. </p>
spellingShingle Asiki, G
Stockdale, L
Kasamba, I
Vudriko, T
Tumwekwase, G
Johnston, T
Kaleebu, P
Kamali, A
Seeley, J
Newton, R
Pilot study of antibodies against varicella zoster virus and human immunodeficiency virus in relation to the risk of developing stroke, nested within a rural cohort in Uganda
title Pilot study of antibodies against varicella zoster virus and human immunodeficiency virus in relation to the risk of developing stroke, nested within a rural cohort in Uganda
title_full Pilot study of antibodies against varicella zoster virus and human immunodeficiency virus in relation to the risk of developing stroke, nested within a rural cohort in Uganda
title_fullStr Pilot study of antibodies against varicella zoster virus and human immunodeficiency virus in relation to the risk of developing stroke, nested within a rural cohort in Uganda
title_full_unstemmed Pilot study of antibodies against varicella zoster virus and human immunodeficiency virus in relation to the risk of developing stroke, nested within a rural cohort in Uganda
title_short Pilot study of antibodies against varicella zoster virus and human immunodeficiency virus in relation to the risk of developing stroke, nested within a rural cohort in Uganda
title_sort pilot study of antibodies against varicella zoster virus and human immunodeficiency virus in relation to the risk of developing stroke nested within a rural cohort in uganda
work_keys_str_mv AT asikig pilotstudyofantibodiesagainstvaricellazostervirusandhumanimmunodeficiencyvirusinrelationtotheriskofdevelopingstrokenestedwithinaruralcohortinuganda
AT stockdalel pilotstudyofantibodiesagainstvaricellazostervirusandhumanimmunodeficiencyvirusinrelationtotheriskofdevelopingstrokenestedwithinaruralcohortinuganda
AT kasambai pilotstudyofantibodiesagainstvaricellazostervirusandhumanimmunodeficiencyvirusinrelationtotheriskofdevelopingstrokenestedwithinaruralcohortinuganda
AT vudrikot pilotstudyofantibodiesagainstvaricellazostervirusandhumanimmunodeficiencyvirusinrelationtotheriskofdevelopingstrokenestedwithinaruralcohortinuganda
AT tumwekwaseg pilotstudyofantibodiesagainstvaricellazostervirusandhumanimmunodeficiencyvirusinrelationtotheriskofdevelopingstrokenestedwithinaruralcohortinuganda
AT johnstont pilotstudyofantibodiesagainstvaricellazostervirusandhumanimmunodeficiencyvirusinrelationtotheriskofdevelopingstrokenestedwithinaruralcohortinuganda
AT kaleebup pilotstudyofantibodiesagainstvaricellazostervirusandhumanimmunodeficiencyvirusinrelationtotheriskofdevelopingstrokenestedwithinaruralcohortinuganda
AT kamalia pilotstudyofantibodiesagainstvaricellazostervirusandhumanimmunodeficiencyvirusinrelationtotheriskofdevelopingstrokenestedwithinaruralcohortinuganda
AT seeleyj pilotstudyofantibodiesagainstvaricellazostervirusandhumanimmunodeficiencyvirusinrelationtotheriskofdevelopingstrokenestedwithinaruralcohortinuganda
AT newtonr pilotstudyofantibodiesagainstvaricellazostervirusandhumanimmunodeficiencyvirusinrelationtotheriskofdevelopingstrokenestedwithinaruralcohortinuganda